Post-Operative Pain - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Post-Operative Pain - Pipeline Review, H2 2016

Post-Operative Pain - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Post-Operative Pain - Pipeline Review, H2 2016
Published Jul 13, 2016
187 pages — Published Jul 13, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Post-Operative Pain - Pipeline Review, H2 2016, provides an overview of the Post-Operative Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Post-Operative Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Post-Operative Pain
- The report reviews pipeline therapeutics for Post-Operative Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Post-Operative Pain therapeutics and enlists all their major and minor projects
- The report assesses Post-Operative Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Post-Operative Pain

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Post-Operative Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Post-Operative Pain pipeline depth and

  
Source:
Document ID
GMDHC8219IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents29
  List of Tables91
  List of Figures101
Introduction111
  Global Markets Direct Report Coverage111
Post-Operative Pain Overview121
Therapeutics Development131
  Pipeline Products for Post-Operative Pain Overview131
Post-Operative Pain Therapeutics under Development by Companies143
Post-Operative Pain Pipeline Products Glance174
  Late Stage Products171
  Clinical Stage Products181
  Early Stage Products191
  Unknown Stage Products201
Post-Operative Pain Products under Development by Companies213
Post-Operative Pain Companies Involved in Therapeutics Development2437
  AcelRx Pharmaceuticals, Inc.241
  Adynxx, Inc.251
  AngioChem Inc.261
  AskAt Inc.271
  Boehringer Ingelheim GmbH281
  Cara Therapeutics, Inc.291
  Colby Pharmaceutical Company301
  Cytogel Pharma, LLC311
  Dompe Farmaceutici S.p.A.321
  DURECT Corporation331
  Echo Pharmaceuticals B.V.341
  Fujimoto Pharmaceutical Corporation351
  Galleon Pharmaceuticals361
  Grunenthal GmbH371
  GW Pharmaceuticals Plc381
  Heron Therapeutics, Inc.391
  Immupharma Plc401
  Innocoll AG411
  INSYS Therapeutics, Inc.421
  Laboratorios Del Dr. Esteve S.A.431
  Lipocure Ltd.441
  Liquidia Technologies, Inc.451
  Medtronic plc461
  Orbis Biosciences, Inc.471
  Orion Oyj481
  Pacira Pharmaceuticals, Inc.491
  PainReform Ltd.501
  Pharmazz, Inc.511
  PhytoHealth Corporation521
  Proteus SA531
  Recro Pharma, Inc.541
  Relmada Therapeutics, Inc.551
  Serina Therapeutics, Inc.561
  SteadyMed Therapeutics, Inc.571
  Takeda Pharmaceutical Company Limited581
  The Medicines Company591
  Trevena, Inc.601
Post-Operative Pain Therapeutics Assessment6112
  Assessment by Monotherapy Products611
  Assessment by Combination Products621
  Assessment by Target633
  Assessment by Mechanism of Action663
  Assessment by Route of Administration692
  Assessment by Molecule Type712
Drug Profiles7397
  (bupivacaine hydrochloride + meloxicam) Drug Profile732
  AM-4 Drug Profile751
  ANG-2002 Drug Profile761
  ARX-04 Drug Profile775
  AYX-1 Drug Profile822
  BI-1026706 Drug Profile841
  bupivacaine hydrochloride Drug Profile851
  bupivacaine hydrochloride Drug Profile861
  bupivacaine hydrochloride Drug Profile871
  bupivacaine hydrochloride Drug Profile881
  bupivacaine hydrochloride ER Drug Profile891
  bupivacaine hydrochloride SR Drug Profile905
  buprenorphine hydrochloride Drug Profile951
  CPC-123 Drug Profile961
  CR-4056 Drug Profile971
  Cyt-1010 Drug Profile982
  dexmedetomidine hydrochloride Drug Profile1003
  DF-2755A Drug Profile1031
  difelikefalin Drug Profile1047
  difluprednate XR Drug Profile1111
  dronabinol Drug Profile1122
  Drug for Post Operative Pain Drug Profile1141
  ECP-1014 Drug Profile1151
  fadolmidine hydrochloride Drug Profile1161
  fentanyl Drug Profile1171
  GAL-044 Drug Profile1181
  grapiprant Drug Profile1192
  IPP-102199 Drug Profile1211
  ketamine hydrochloride Drug Profile1222
  ketorolac tromethamine Drug Profile1241
  levorphanol tartrate ER Drug Profile1252
  MDT-10013 Drug Profile1271
  meloxicam Drug Profile1283
  meloxicam ER Drug Profile1311
  meloxicam ER Drug Profile1321
  MR-309 Drug Profile1332
  nabiximols Drug Profile1357
  nalbuphine hydrochloride Drug Profile1421
  neosaxitoxin Drug Profile1432
  oliceridine Drug Profile1455
  PMZ-2010 Drug Profile1501
  RBM-004 Drug Profile1511
  ropivacaine Drug Profile1521
  ropivacaine ER Drug Profile1531
  SER-226 Drug Profile1541
  Small Molecule for Post-Operative Pain Drug Profile1551
  sufentanil citrate Drug Profile1568
  tapentadol hydrochloride Drug Profile1642
  tramadol hydrochloride Drug Profile1661
  tramadol hydrochloride ER Drug Profile1671
  URB-937 Drug Profile1681
  VVZ-149 Drug Profile1691
Post-Operative Pain Dormant Projects1705
Post-Operative Pain Discontinued Products1751
Post-Operative Pain Product Development Milestones17610
  Featured News &Press Releases1761
    Jun 13, 2016: Initiation of Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug SyB P-1501 1761
    Jun 08, 2016: Trevena Announces First Patients Enrolled in the APOLLO-1 and APOLLO-2 Phase 3 Pivotal Efficacy Studies of Oliceridine in Acute Pain1761
    Jun 06, 2016: Cara Therapeutics Resumes Patient Recruitment for Adaptive Phase 3 Trial of I.V. CR845 in Postoperative Pain1771
    Apr 20, 2016: Cara Therapeutics Announces Removal of FDA Clinical Hold on CLIN3001 Postoperative Pain Trial for I.V. CR8451771
    Apr 07, 2016: DURECT Announces POSIMIR Program Update1781
    Mar 07, 2016: AcelRx Pharmaceuticals Initiates Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain1791
    Mar 07, 2016: iX Biopharma Reports Positive Results From Multi-Dose Waferminetm Clinical Trial1791
    Feb 25, 2016: AcelRx Pharmaceuticals Moderate-to-Severe Acute Pain Candidate ARX-04 Shows Improved Pain Scores in ER Patients in Interim Phase 3 Analysis1801
    Feb 25, 2016: Cara Therapeutics Provides Update on CLIN3001 Postoperative Pain Trial for I.V. CR8451801
    Feb 01, 2016: Recro Pharma Initiates Second Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain1811
    Jan 27, 2016: Recro Pharma Initiates Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain1821
    Jan 21, 2016: AcelRx Pharmaceuticals Announces Presentation of Phase 3 Sufentanil Sublingual 30 mcg Tablet (ARX-04) Data at the European Congress of Ambulatory Surgery1821
    Dec 23, 2015: AcelRx Pharmaceuticals Receives Notice of Eligibility for Centralized Review of ARX-04 from European Medicines Agency1831
    Dec 14, 2015: AcelRx Pharmaceuticals Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-041831
    Nov 20, 2015: The Medicines Company Receives European Commission Approval for IONSYS 40 micrograms per dose transdermal system (fentanyl) to Treat Post-Operative Pain in Adult Hospitalized Patients1842
Appendix1862
  Methodology1861
  Coverage1861
  Secondary Research1861
  Primary Research1861
  Expert Panel Validation1861
  Contact Us1861
  Disclaimer1871

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Post-Operative Pain - Pipeline Review, H2 2016" Jul 13, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Post-Operative-Pain-Pipeline-Review-H2-2016-2088-16154>
  
APA:
Global Markets Direct - Market Research. (2016). Post-Operative Pain - Pipeline Review, H2 2016 Jul 13, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Post-Operative-Pain-Pipeline-Review-H2-2016-2088-16154>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.